Patents by Inventor Michael Crager

Michael Crager has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA methylation and mutational analysis methods for bladder cancer surveillance
    Patent number: 11649506
    Abstract: The present disclosure relates to methods of monitoring bladder cancer patients and analyzing patient samples for presence of methylated DNA and optionally particular gene mutations. In some embodiments, analysis results are correlated with clinical outcome measures such as risk of bladder cancer recurrence.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: May 16, 2023
    Assignee: Genomic Health, Inc.
    Inventors: Margarita Lopatin, Athanasios Tsiatis, Christopher N. Silk, David P. Miller, Michael Crager, Phillip Febbo, Dejan Knezevic
  • METHOD FOR USING GENE EXPRESSION TO DETERMINE PROGNOSIS OF PROSTATE CANCER
    Publication number: 20220396842
    Abstract: The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.
    Type: Application
    Filed: August 19, 2022
    Publication date: December 15, 2022
    Inventors: Steven SHAK, Frederick L. Baehner, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
  • Method for Using Gene Expression to Determine Prognosis of Prostate Cancer
    Publication number: 20200255911
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: February 25, 2020
    Publication date: August 13, 2020
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Steven SHAK, Frederick L. BAEHNER, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
  • DNA Methylation and Mutational Analysis Methods for Bladder Cancer Surveillance
    Publication number: 20200165686
    Abstract: The present disclosure relates to methods of monitoring bladder cancer patients and analyzing patient samples for presence of methylated DNA and optionally particular gene mutations. In some embodiments, analysis results are correlated with clinical outcome measures such as risk of bladder cancer recurrence.
    Type: Application
    Filed: May 17, 2018
    Publication date: May 28, 2020
    Applicant: Genomic Health, Inc.
    Inventors: Margarita LOPATIN, Athanasios TSIATIS, Christopher N. SILK, David P. Miller, Michael CRAGER, Phillip FEBBO, Dejan KNEZEVIC
  • Algorithms and Methods for Assessing Late Clinical Endpoints in Prostate Cancer
    Publication number: 20200040400
    Abstract: The present disclosure relates to uses of a multiple gene-expression based Genomic Prostate Score™ (GPS™) algorithm for assessment of various clinical endpoints in prostate cancer patients, such as risks of clinical recurrence (CR), biochemical recurrence (BCR), distant metastasis (Mets), and prostate cancer death (PCD). In some embodiments, GPS result is determined for low and intermediate risk prostate cancer patients in order to assist in determining treatment strategies for those patients.
    Type: Application
    Filed: February 12, 2018
    Publication date: February 6, 2020
    Applicant: Genomic Health, Inc.
    Inventors: Ruixiao LU, Michael CRAGER, Nan ZHANG, Tara MADDALA, Phillip FEBBO, Hugh Jeffrey LAWRENCE
  • Method for Using Gene Expression to Determine Prognosis of Prostate Cancer
    Publication number: 20190249260
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: February 22, 2019
    Publication date: August 15, 2019
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Steven SHAK, Frederick L. BAEHNER, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
  • Method for using gene expression to determine prognosis of prostate cancer
    Patent number: 10260104
    Abstract: The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: April 16, 2019
    Assignee: Genomic Health, Inc.
    Inventors: Steven Shak, Frederick L. Baehner, Tara Maddala, Mark Lee, Robert J. Pelham, Wayne Cowens, Diana Cherbavaz, Michael C. Kiefer, Michael Crager, Audrey Goddard, Joffre B. Baker
  • METHOD FOR USING GENE EXPRESSION TO DETERMINE PROGNOSIS OF PROSTATE CANCER
    Publication number: 20160097105
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: October 20, 2015
    Publication date: April 7, 2016
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Steven SHAK, Frederick L. BAEHNER, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
  • Methods of predicting cancer risk using gene expression in premalignant tissue
    Patent number: 8765383
    Abstract: The present disclosure provides methods for assessing a patient's cancer risk and/or recurrence risk, which methods comprise assaying, in a biological sample obtained from the gastrointestinal (GI) tract of the patient, an expression level of a risk gene. The present disclosure also provides methods involving a cancer risk/recurrence risk sequence, i.e. the V600E mutation of the BRAF gene, which is useful for assessing cancer risk and/or recurrence risk in a patient.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: July 1, 2014
    Assignee: Genomic Health, Inc.
    Inventors: Wayne Cowens, Maureen T. Cronin, Carl L. Millward, Francois Collin, Michael Crager
  • Gene expression profile algorithm and test for determining prognosis of prostate cancer
    Patent number: 8725426
    Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: May 13, 2014
    Assignee: Genomic Health, Inc.
    Inventors: Steve Shak, Mark Lee, William Novotny, Tara Maddala, Michael Crager, Diana Cherbavaz, Robert J. Pelham, Carl L. Millward, Dejan Knezevic
  • METHOD FOR USING GENE EXPRESSION TO DETERMINE PROGNOSIS OF PROSTATE CANCER
    Publication number: 20120028264
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: July 25, 2011
    Publication date: February 2, 2012
    Inventors: Steven Shak, Frederick L. Baehner, Tara Maddala, Mark Lee, Robert J. Pelham, Wayne Cowens, Diana Cherbavaz, Michael C. Kiefer, Michael Crager, Audrey Goddard, Joffre B. Baker
  • Methods of Predicting Cancer Risk Using Gene Expression in Premalignant Tissue
    Publication number: 20100291573
    Abstract: The present disclosure provides methods for assessing a patient's cancer risk and/or recurrence risk, which methods comprise assaying, in a biological sample obtained from the gastrointestinal (GI) tract of the patient, an expression level of a risk gene. The present disclosure also provides methods involving a cancer risk/recurrence risk sequence, i.e. the V600E mutation of the BRAF gene, which is useful for assessing cancer risk and/or recurrence risk in a patient.
    Type: Application
    Filed: April 6, 2010
    Publication date: November 18, 2010
    Inventors: Wayne Cowens, Maureen T. Cronin, Carl L. Millward, Francois Collin, Michael Crager
  • Methods of treating idiopathic pulmonary fibrosis
    Publication number: 20080057030
    Abstract: The present invention provides methods of treating idiopathic pulmonary fibrosis (IPF); methods of increasing survival time in an individual with IPF; and methods of reducing risk of death in an individual with IPF. The methods generally involve administering a therapeutically effective amount of IFN-? to an individual with IPF.
    Type: Application
    Filed: August 21, 2003
    Publication date: March 6, 2008
    Inventor: Michael Crager
  • Methods of treating idiopathic pulmonary fibrosis
    Publication number: 20070053877
    Abstract: The present application provides methods of treating idiopathic pulmonary fibrosis (IPF); methods of increasing survival time in an individual with IPF, and methods of reducing risk of death in an individual with IPF. The methods generally involve administering a therapeutically effective amount of IFN-? to an individual with IPF.
    Type: Application
    Filed: July 17, 2006
    Publication date: March 8, 2007
    Applicant: INTERMUNE, INC.
    Inventors: Michael Crager, Scott Harkonen